Cargando…
EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-making
INTRODUCTION: A review of European Union (EU)-funded initiatives linked to ‘Real World Evidence’ (RWE) was performed to determine whether their outputs could be used for the generation of real-world data able to support the European Medicines Agency (EMA)’s regulatory decision-making on medicines. M...
Autores principales: | Plueschke, Kelly, McGettigan, Patricia, Pacurariu, Alexandra, Kurz, Xavier, Cave, Alison |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009620/ https://www.ncbi.nlm.nih.gov/pubmed/29903798 http://dx.doi.org/10.1136/bmjopen-2018-021864 |
Ejemplares similares
-
Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation
por: Pacurariu, Alexandra, et al.
Publicado: (2018) -
Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe
por: Cave, Alison, et al.
Publicado: (2019) -
Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
por: Bakker, Elisabeth, et al.
Publicado: (2022) -
Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe
por: Jonker, Carla J., et al.
Publicado: (2022) -
Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments
por: McGettigan, Patricia, et al.
Publicado: (2019)